BioNTech
- Country
- 🇩🇪Germany
- Ownership
- Public
- Employees
- 6.1K
- Market Cap
- $20.7B
- Website
- http://www.biontech.de
- Introduction
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
Clinical Trials
110
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (105 trials with phase data)• Click on a phase to view related trials
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: SoC chemotherapy treatment 1Drug: SoC chemotherapy treatment 2
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 482
- Registration Number
- NCT07079631
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 550
- Registration Number
- NCT07070232
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Adults, Including Those at Higher Risk of Severe COVID-19
- Conditions
- COVID-19SARS-COV-2 Infection
- Interventions
- Biological: BNT162b2 (Omi LP.8.1)
- First Posted Date
- 2025-07-16
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 100
- Registration Number
- NCT07069309
- Locations
- 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸Indago Research & Health Center, Inc, Hialeah, Florida, United States
🇺🇸Bio-Kinetic Clinical Applications, LLC dba QPS-MO, Springfield, Missouri, United States
A Clinical Study Investigating the Therapeutic Effects and Safety of an Investigational Cell Therapy Given With and Without an Additional Investigational Product in Males With Testicular Cancer or a Form of Cancer That Developed From Sperm
- Conditions
- Testicular Germ Cell TumorExtragonadal Germ Cell Tumor
- Interventions
- Biological: CLDN6 CAR-T
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 150
- Registration Number
- NCT06940804
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 594
- Registration Number
- NCT06892548
- Locations
- 🇺🇸
Precision NextGen Oncology and Research Center, Beverly Hills, California, United States
🇺🇸Virginia Cancer Specialists, Fairfax, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer
Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.
EU Regulatory Approval Advances Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for 2025-2026 Season
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.
Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes
A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.
BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure
Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.
Regeneron and BioNTech Advance Phase 2 Trial Combining Cancer Vaccine BNT116 with Cemiplimab for Advanced NSCLC
Regeneron Pharmaceuticals and BioNTech SE are conducting a Phase 2 clinical trial evaluating the combination of investigational cancer vaccine BNT116 with cemiplimab versus cemiplimab monotherapy in advanced non-small cell lung cancer patients with PD-L1 expression ≥50%.
Sartorius Stedim Biotech Partners with Sensible Biotechnologies to Scale Cell-Based mRNA Manufacturing Platform
Sartorius Stedim Biotech and Sensible Biotechnologies have signed a Memorandum of Understanding to advance the industrialization of Sensible's first-in-class cell-based mRNA manufacturing platform.
Everest Medicines Advances AI-Powered mRNA Platform with Cancer Vaccine Breakthroughs
Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.
NCT/UCC Dresden Launches Phase 2 Trial of Personalized mRNA Vaccine for Pancreatic Cancer
NCT/UCC Dresden becomes the only site in Saxony to offer patients access to BioNTech and Genentech's personalized mRNA vaccine Autogene Cevumeran for pancreatic cancer treatment.
BioNTech Shuts Down Maryland Cell Therapy Manufacturing Following CAR-T Trial Failure
BioNTech will lay off 63 employees and wind down cell therapy manufacturing at its Gaithersburg, Maryland facility by the end of 2025 following disappointing Phase 1 trial results.
BioNTech to Acquire CureVac for $1.25 Billion to Strengthen mRNA Cancer Immunotherapy Pipeline
BioNTech announced a $1.25 billion all-stock acquisition of CureVac through a public exchange offer, offering $5.46 per CureVac share representing a 55% premium to strengthen its mRNA-based cancer immunotherapy capabilities.